c-Myc

Expression of c-myc and mutation of the KRAS gene in patients with ovarian mucinous tumors

X. S. Li, Sun, J., and He, X. L., Expression of c-myc and mutation of the KRAS gene in patients with ovarian mucinous tumors, vol. 14, pp. 10752-10759, 2015.

We examined the expression of c-myc and mutations in the KRAS gene in ovarian mucinous tumors to explore the pathogenesis of these tumors and the feasibility of targeted gene therapy. Expression of c-myc protein and mutations in the KRAS gene in 24 cases of ovarian mucinous cystadenoma, 46 cases of ovarian borderline mucinous cystadenoma, and 46 cases of ovarian mucinous cystadenocarcinoma were detected using the immunohistochemistry PV-9000 2-step method and polymerase chain reaction-restriction fragment length polymorphism.

Effect of recombinant human endostatin on the expression of c-Myc and bFGF in mouse gastric cancer cells

Z. Y. Guo, Yao, G. D., Fu, L. P., Fu, Z. G., and Hou, B., Effect of recombinant human endostatin on the expression of c-Myc and bFGF in mouse gastric cancer cells, vol. 14, pp. 5258-5265, 2015.

The aim of this study was to observe the effects of re­combinant human endostatin on the proliferation and apoptosis of mouse gastric cancer cells, and explore some possible mechanisms of recom­binant human endostatin inhibition of cancer. A murine gastric cancer xenograft model was established. A total of 20 mice were divided into two groups (control and experimental groups). The expression of c-Myc and basic fibroblast growth factor (bFGF) was determined by reverse transcription-polymerase chain reaction, Western blotting, and immu­nohistochemical staining methods.

5-Azacytidine suppresses the proliferation of pancreatic cancer cells by inhibiting the Wnt/β-catenin signaling pathway

H. Zhang, Zhou, W. C., Li, X., Meng, W. B., Zhang, L., Zhu, X. L., Zhu, K. X., Bai, Z. T., Yan, J., Liu, T., Xu, X. C., and Li, Y. M., 5-Azacytidine suppresses the proliferation of pancreatic cancer cells by inhibiting the Wnt/β-catenin signaling pathway, vol. 13, pp. 5064-5072, 2014.

5-Azacytidine has been shown to be an effective anti-pancreatic cancer drug, but the mechanism remains unknown. In the current study, we explored the effect of 5-azacytidine on abnormal activation of the Wnt-β-catenin signaling pathway in pancreatic cancer cells. The human pancreatic cancer cell line Bxpc-3 was treated with different concentrations of 5-azacytidine for various times. The proliferation and early apoptosis of the cells were evaluated using the CCK8 method and flow cytometry, respectively.

Subscribe to c-Myc